Mutational spectrum of BRAF gene in colorectal cancer patients in Saudi Arabia.

BRAF gene Colorectal cancer Homology modeling Mutational Screening Nucleotide variants Swiss Model

Journal

Saudi journal of biological sciences
ISSN: 1319-562X
Titre abrégé: Saudi J Biol Sci
Pays: Saudi Arabia
ID NLM: 101543796

Informations de publication

Date de publication:
Oct 2021
Historique:
received: 11 05 2021
revised: 15 06 2021
accepted: 16 06 2021
entrez: 30 9 2021
pubmed: 1 10 2021
medline: 1 10 2021
Statut: ppublish

Résumé

Colorectal cancer (CRC) is one of the topmost causes of death in males in Saudi Arabia. In females, it was also within the top five cancer types. CRC is heterogeneous in terms of pathogenicity and molecular genetic pathways. It is very important to determine the genetic causes of CRC in the Saudi population. BRAF is one of the major genes involved in cancers, it participates in transmitting chemical signals from outside the cells into the nucleus of the cells and it is also shown to participate in cell growth. In this study, we mapped the spectrum of BRAF mutations in 100 Saudi patients with CRC. We collected tissue samples from colorectal cancer patients, sequenced the BRAF gene to identify gene alterations, and analyzed the data using different bioinformatics tools. We designed a three-dimensional (3D) homology model of the BRAF protein using the Swiss Model automated homology modeling platform to study the structural impact of these mutations using the Missense3D algorithm. We found six mutations in 14 patients with CRC. Four of these mutations are being reported for the first time. The novel frameshift mutations observed in CRC patients, such as c.1758delA (E586E), c.1826insT (Q609L), c.1860insA and c.1860insA/C (M620I), led to truncated proteins of 589, 610, and 629 amino acids, respectively, and potentially affected the structure and the normal functions of BRAF. These findings provide insights into the molecular etiology of CRC in general and to the Saudi population. BRAF genetic testing may also guide treatment modalities, and the treatment may be optimized based on personalized gene variations.

Identifiants

pubmed: 34588906
doi: 10.1016/j.sjbs.2021.06.048
pii: S1319-562X(21)00517-9
pmc: PMC8459112
doi:

Types de publication

Journal Article

Langues

eng

Pagination

5906-5912

Informations de copyright

© 2021 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Références

PLoS Comput Biol. 2021 Jan 28;17(1):e1008667
pubmed: 33507980
Recent Prog Horm Res. 2001;56:127-55
pubmed: 11237210
BMC Bioinformatics. 2019 Sep 14;20(1):473
pubmed: 31521110
Sci Rep. 2017 Sep 5;7(1):10480
pubmed: 28874689
J Gastrointest Oncol. 2015 Dec;6(6):660-7
pubmed: 26697199
Acta Crystallogr D Biol Crystallogr. 2010 Jan;66(Pt 1):12-21
pubmed: 20057044
J Cell Biol. 2012 Jul 23;198(2):185-94
pubmed: 22826122
J Natl Compr Canc Netw. 2018 Aug;16(8):939-949
pubmed: 30099370
Oncotarget. 2016 Aug 16;7(33):53959-53983
pubmed: 27276710
JAMA Surg. 2015 Jan;150(1):17-22
pubmed: 25372703
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Genet. 2006 Jul;38(7):787-93
pubmed: 16804544
BMC Bioinformatics. 2009 Dec 15;10:421
pubmed: 20003500
Cancer Res. 1998 Apr 15;58(8):1713-8
pubmed: 9563488
J Mol Biol. 1963 Jul;7:95-9
pubmed: 13990617
Nature. 2019 Nov;575(7783):545-550
pubmed: 31581174
Ann Saudi Med. 2015 May-Jun;35(3):196-202
pubmed: 26409793
CA Cancer J Clin. 2017 May 6;67(3):177-193
pubmed: 28248415
Nucleic Acids Res. 2017 Jan 4;45(D1):D170-D176
pubmed: 27899574
JAAPA. 2018 Dec;31(12):10-11
pubmed: 30418294
Nucleic Acids Res. 2017 Jan 4;45(D1):D158-D169
pubmed: 27899622
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Clin Colorectal Cancer. 2018 Mar;17(1):73-79
pubmed: 29128266
Int J Mol Sci. 2019 Oct 28;20(21):
pubmed: 31661924
BMC Cancer. 2015 Oct 24;15:779
pubmed: 26498038
Biomark Cancer. 2015 Sep 06;7(Suppl 1):9-12
pubmed: 26396549
Ther Adv Med Oncol. 2019 Jun 18;11:1758835919856494
pubmed: 31244912
N Engl J Med. 1988 Sep 1;319(9):525-32
pubmed: 2841597
Bioinformatics. 2020 Mar 1;36(6):1765-1771
pubmed: 31697312
J Mol Biol. 2019 May 17;431(11):2197-2212
pubmed: 30995449
Nucleic Acids Res. 2017 Jan 4;45(D1):D313-D319
pubmed: 27899672
Mayo Clin Proc. 2014 Feb;89(2):216-24
pubmed: 24393412
Nucleic Acids Res. 2018 Jul 2;46(W1):W296-W303
pubmed: 29788355

Auteurs

Mahmood Rasool (M)

Center of Excellence in Genomic Medicine Research, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.

Peter Natesan Pushparaj (P)

Center of Excellence in Genomic Medicine Research, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.

Abdelbaset Buhmeida (A)

Center of Excellence in Genomic Medicine Research, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.

Sajjad Karim (S)

Center of Excellence in Genomic Medicine Research, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.

Classifications MeSH